The Chinese business of Roche (ROG: SIX) has announced a new partnership with Hong Kong-listed Ascletis (HK: 1672) in viral hepatitis.
The firms previously partnered to launch Ganovo (danoprevir), and will now work together to sell Pegasys (peginterferon alfa 2a) in China.
Ascletis will gain an exclusive sales and marketing promotion right in China for the pegylated interferon treatment for hepatitis B and C. It is estimated that over 86 million people in China are chronically infected with hepatitis B virus (HBV).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze